LivaNova Gelecekteki Büyüme

Future kriter kontrolleri 3/6

LivaNova kazanç ve gelirin sırasıyla yıllık 48.1% ve 4.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 33.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

48.1%

Kazanç büyüme oranı

33.7%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.2%
Gelir büyüme oranı	4.4%
Gelecekteki özkaynak getirisi	7.7%
Analist kapsamı	Good
Son güncelleme	12 Nov 2024

Gelecekteki son büyüme güncellemeleri

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Nov 03

Recent updates

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

Nov 12

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Nov 03

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

Nov 08

At US$47.94, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?

Oct 16

Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 44%?

Sep 25

Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal

Jul 26

Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$51.43?

Jul 03

An Intrinsic Calculation For LivaNova PLC (NASDAQ:LIVN) Suggests It's 37% Undervalued

Jun 09

Investors Could Be Concerned With LivaNova's (NASDAQ:LIVN) Returns On Capital

Apr 13

What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?

Mar 13

Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)

Feb 15

Returns At LivaNova (NASDAQ:LIVN) Are On The Way Up

Nov 25

Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?

Oct 29

LivaNova Loses Profit Momentum On Higher R&D Expense

Oct 13

LivaNova PLC (NASDAQ:LIVN) Shares Could Be 30% Below Their Intrinsic Value Estimate

Oct 11

FDA labels recall of blood bypass pump systems by LivaNova as most serious

Sep 30

Returns On Capital At LivaNova (NASDAQ:LIVN) Have Hit The Brakes

Aug 09

LivaNova PLC Non-GAAP EPS of $0.53 beats by $0.01, revenue of $254.2M beats by $4.65M, lowers FY earning guidance

Aug 03

Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?

Jul 19

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:LIVN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,386	121	299	N/A	10
12/31/2025	1,312	41	476	N/A	10
12/31/2024	1,245	0	729	N/A	10
9/30/2024	1,242	24	109	158	N/A
6/30/2024	1,210	-17	85	125	N/A
3/31/2024	1,185	-32	30	64	N/A
12/31/2023	1,154	18	40	75	N/A
9/30/2023	1,118	3	8	40	N/A
6/30/2023	1,085	-97	29	57	N/A
3/31/2023	1,045	-82	36	65	N/A
12/31/2022	1,022	-86	43	70	N/A
9/30/2022	1,017	-93	60	85	N/A
6/30/2022	1,018	-29	51	73	N/A
3/31/2022	1,028	-102	86	109	N/A
12/31/2021	1,035	-136	77	103	N/A
9/30/2021	1,035	-414	82	106	N/A
6/30/2021	1,022	-385	59	91	N/A
3/31/2021	939	-417	11	46	N/A
12/31/2020	934	-347	-114	-79	N/A
9/30/2020	952	-208	-150	-114	N/A
6/30/2020	981	-161	-234	-199	N/A
3/31/2020	1,076	-102	-230	-199	N/A
12/31/2019	1,084	-158	-116	-91	N/A
9/30/2019	1,094	-222	-106	-73	N/A
6/30/2019	1,097	-260	19	55	N/A
3/31/2019	1,107	-211	63	102	N/A
12/31/2018	1,107	-178	82	120	N/A
9/30/2018	1,088	0	82	117	N/A
6/30/2018	1,068	33	N/A	108	N/A
3/31/2018	1,036	59	N/A	79	N/A
12/31/2017	1,012	54	N/A	91	N/A
9/30/2017	795	121	N/A	114	N/A
6/30/2017	840	92	N/A	109	N/A
3/31/2017	905	55	N/A	114	N/A
12/31/2016	965	2	N/A	90	N/A
12/31/2015	545	-22	N/A	-14	N/A
10/18/2015	295	14	N/A	87	N/A
7/24/2015	301	57	N/A	80	N/A
4/24/2015	292	58	N/A	80	N/A
1/23/2015	292	66	N/A	80	N/A
10/24/2014	288	63	N/A	75	N/A
7/25/2014	285	60	N/A	63	N/A
4/25/2014	282	55	N/A	54	N/A
1/24/2014	276	48	N/A	61	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: LIVN 'nin tahmini kazanç büyümesi (yıllık 48.1% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: LIVN şirketinin kazançlarının (yıllık 48.1% ) US pazarından (yıllık 15.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: LIVN şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: LIVN şirketinin gelirinin (yıllık 4.4% ) US pazarından (yıllık 9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: LIVN şirketinin gelirinin (yıllık 4.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: LIVN 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7.7 %).

LivaNova Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

LivaNova PLC Provides Earnings Guidance for the Year 2024

LivaNova PLC Provides Earnings Guidance for the Full-Year 2024

Consensus EPS estimates fall by 12%, revenue upgraded

Livanova plc Provides Revenue Guidance for the Full-Year 2023

Price target increased by 7.7% to US$65.33

Recent updates

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

LivaNova PLC Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

High number of new directors

LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital

LivaNova: Economics Should Start Making Sustained Improvements

LivaNova PLC Appoints Susan Podlogar as New Director

Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 31%?

LivaNova PLC to Report Q3, 2024 Results on Oct 30, 2024

Trui Hebbelinck Leaves Position of LivaNova Plc's Chief Human Resources Officer

LivaNova PLC's (NASDAQ:LIVN) Prospects Need A Boost To Lift Shares

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova PLC Provides Earnings Guidance for the Year 2024

LivaNova (NASDAQ:LIVN) Might Have The Makings Of A Multi-Bagger

At US$52.79, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?

LivaNova PLC to Report Q2, 2024 Results on Jul 31, 2024

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?

LivaNova PLC Provides Update on Recover Clinical Study Evaluating Vns Therapy for Treatment-Resistant Depression in Unipolar Patients

Independent Director notifies of intention to sell stock

LivaNova: Focus Is Paying Off

Now 21% undervalued

LivaNova PLC Provides Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova PLC, Annual General Meeting, Jun 11, 2024

These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong

Chief Financial Officer exercised options and sold US$353k worth of stock

LivaNova PLC to Report Q1, 2024 Results on May 01, 2024

Now 21% overvalued after recent price rise

LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% overvalued after recent price rise

Livanova plc Announces Impairment Charges for the Three Month Ended December 31, 2023

LivaNova PLC Announces CEO Changes, Effective on March 1, 2024

Is It Time To Consider Buying LivaNova PLC (NASDAQ:LIVN)?

A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)

LivaNova PLC to Report Q4, 2023 Results on Feb 21, 2024

LivaNova PLC's (NASDAQ:LIVN) Business And Shares Still Trailing The Industry

LivaNova (NASDAQ:LIVN) Could Be At Risk Of Shrinking As A Company

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

New minor risk - Earnings quality

Livanova plc Provides Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

At US$47.94, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?

LivaNova PLC Announces Board Changes

Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 44%?

Marco Dolci to Retire as President of Cardiopulmonary Business Unit of LivaNova PLC on December 31, 2023

LivaNova PLC to Report Q3, 2023 Results on Nov 01, 2023

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

Price target increased by 7.7% to US$65.33

LivaNova PLC Provides Financial Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal

Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$51.43?

LivaNova PLC to Report Q2, 2023 Results on Jul 26, 2023

LivaNova PLC Announces 150th Bipolar Depression Patient Randomized in Recover Clinical Study

An Intrinsic Calculation For LivaNova PLC (NASDAQ:LIVN) Suggests It's 37% Undervalued

LivaNova PLC Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.1% to US$62.25

Investors Could Be Concerned With LivaNova's (NASDAQ:LIVN) Returns On Capital

CEO & Director exercised options and sold US$432k worth of stock

What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?

CEO & Director exercised options and sold US$805k worth of stock

Full year 2022 earnings released: US$1.61 loss per share (vs US$2.68 loss in FY 2021)

Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)